G1 Therapeutics Inc.
Pausing the cell cycle to protect cancer patients' bone marrow
This article was originally published in Start Up
Executive Summary
Bone marrow suppression is arguably the worst side effect of chemotherapy, and to limit the damage chemotherapies do to healthy cells, clinicians now frequently follow protocols that call for supportive treatment with red blood cell stimulator EPO and/or GCSF. G1 Therapeutics Inc.’s drug candidate could one day displace growth factors by temporarily halting the growth of blood cells and their progenitors in the bone marrow so they can evade chemotherapies that target dividing cells.